Russell's viper venom toxins (Daboia russelii venom toxins) (RVV)

Russell's viper venom toxins (RVV) represent a complex mixture of enzymes and non-enzymatic proteins secreted by the Russell's viper (Daboia russelii), a species responsible for the majority of fatal snakebites in South and Southeast Asia (World Health Organization, 2021). The venom's primary biological function is to immobilize and digest prey through potent hemotoxic, nephrotoxic, and sometimes neurotoxic activities (UniProt Consortium, 2023). Key components include Factor X and Factor V activators, which trigger venom-induced consumption coagulopathy (VICC), and phospholipase A2 (PLA2) enzymes that cause systemic inflammation and renal failure (Mukherjee, 2014). These toxins act by rapidly depleting clotting factors in the host, leading to uncontrollable bleeding and potential organ failure. In clinical medicine, these toxins are the primary targets for antivenom therapy, where specific antibodies bind and neutralize the venom's enzymatic components (World Health Organization, 2021). Emerging therapeutic strategies also explore the use of small-molecule inhibitors, such as varespladib for PLA2 and marimastat for metalloproteinases, to provide rapid intervention against the venom's destructive effects (Lewin et al., 2016). Additionally, specific toxins like the Factor X activator are utilized in diagnostic assays to evaluate blood coagulation disorders (UniProt Consortium, 2023). Understanding the molecular diversity of these toxins is crucial for developing more effective, geographically specific antivenoms and novel pharmacological agents.

Other names

Daboia russelii venomRussell's viper venomRVVDaboia russelii toxinsRussell's viper venom factor X activatorRussell's viper venom factor V activator

Antibody-mediated neutralization of enzymatic and non-enzymatic toxins; competitive and non-competitive inhibition of phospholipase A2 and metalloproteinases.